Clatot F, Perdrix A, Beaussire L, Lequesne J, et al. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer. Breast Cancer Res 2020;22:56.
PMID: 32466779